Company intelligence / Profile preview

Biomed Industries

San Jose, California, United Statesbiomedind.com ↗

Ownership: Private
Development stage: Other

Overview

NA‑831 has shown significant efficacy and safety in a Phase 2 clinical trial for Alzheimer’s disease with improvement in cognitive scores and no major adverse events. The company is advancing to Phase 3 trials. Other candidates have demonstrated promising safety profiles and early efficacy signals for MDD, Rett Syndrome, ALS/Parkinson's Disease, and obesity/metabolic disorders[4][5].

Therapeutic areas: PsychiatryNeurologyMetabolic Disorders
Modalities: Small moleculeDevice (for MICROS infusion system)
Industry: Biotech

Drug pipeline

1 asset

NA-932

Preclinical

Beyond the preview

Go deeper on Biomed Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomed Industries.

Explore the full profile